Bristol-Myers Squibb Co (BMY) Position Boosted by Engineers Gate Manager LP
Engineers Gate Manager LP boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 35.7% in the 4th quarter, HoldingsChannel reports. The fund owned 52,327 shares of the biopharmaceutical company’s stock after purchasing an additional 13,774 shares during the period. Engineers Gate Manager LP’s holdings in Bristol-Myers Squibb were worth $3,207,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Delphi Private Advisors LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $108,000. Atlantic Trust LLC bought a new stake in Bristol-Myers Squibb during the second quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC lifted its position in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. lifted its position in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Finally, Horan Capital Advisors LLC. bought a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $122,000. 70.57% of the stock is owned by institutional investors.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the business posted $0.63 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 2.42%. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.
Several equities research analysts have issued reports on BMY shares. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a research report on Thursday, December 28th. BMO Capital Markets reiterated a “sell” rating and set a $52.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, January 22nd. Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $51.56 to $78.00 in a research report on Thursday, February 15th. Finally, Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $66.18.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/03/05/bristol-myers-squibb-co-bmy-position-boosted-by-engineers-gate-manager-lp.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.